Established in 1964 as Yamamoto Medical Corporation, Cellforce One Clinic Tokyo operates as a filed regenerative medicine provider under Japan's Act on Safety of Regenerative Medicine (Type II & III), delivering the DDR Protocol — Detect, Review, Rebuild — from Ginza, Tokyo.
Yamamoto Medical Corporation was established in 1964, building over 60 years of clinical heritage across generations. Cellforce One Clinic Tokyo draws on this foundation as a filed regenerative medicine provider (Type II & III) under Japan's Act on Safety of Regenerative Medicine, delivering precision cellular therapies from Ginza, Tokyo.
Japan's Act on Safety of Regenerative Medicine (Act No. 85 of 2013) establishes a formal framework for providing regenerative medicine in Japan. Cellforce One Clinic Tokyo manages five filed provision plans, six related cell-processing / operational contracts, annual or periodic reporting, and the necessary filing records.
MSC consultation is handled under filed Category II provision plans. Chronic pain plans include PB3240161 / PB3250154, and osteoarthritis plans include PB3240166 / PB3250155. The physician reviews the route, risks, costs, and alternatives before any treatment decision.
NK cell therapy is filed / notified as a Category III regenerative-medicine provision plan (Plan No. PB3250244). Filing describes the provision framework; it is not a national efficacy or safety endorsement by the Ministry of Health, Labour and Welfare.
When specialist evaluation or higher-level care is appropriate, the clinic organizes records, imaging, referral letters, and consultation history so the next medical institution can review the case clearly.
Full member of Japan's leading regenerative medicine academic society. Clinical protocols are continuously updated in accordance with the latest evidence, including the society's YOKOHAMA Declaration 2025 framework for Explorative Therapies.
The first step is to understand the body condition: imaging, bloodwork, inflammation / immune context, medical history, medications, and prior records. NK, MSC, referral, follow-up, or no regenerative-medicine procedure may each be appropriate depending on physician review.
MRI, blood panels, inflammation markers, immune context, and prior medical records are organized before discussing regenerative-medicine options. No single test determines the decision by itself.
NK cells are discussed only after screening and physician review. The filed plan number is PB3250244; consultation covers purpose, route, risks, costs, alternatives, and whether standard specialist care should be prioritized.
MSC consultation is considered within filed Category II provision plans. Chronic pain is primarily reviewed for intravenous infusion, while osteoarthritis is reviewed for intra-articular administration where appropriate.
Decision rationale: A regenerative-medicine discussion starts from records, imaging, bloodwork, inflammation context, medical history, and physician consultation. Filing status and plan numbers describe the provider framework; they do not promise individual outcomes.
A physician-led management structure is used for informed consent, adverse-event response, record handling, self-pay explanation, and referral preparation where specialist care or higher-level evaluation is appropriate.
The clinic manages five filed provision plans and the related annual / periodic reporting workflow. Treatments are discussed only within the scope of the applicable plan, physician judgment, consent, and individual risk review.
Six related cell-processing / operational contracts support the provision framework. The relevant facility, quality documents, lot / route records, and risk explanation are checked for each case before a physician-led decision.
As Yamamoto Medical Corporation, the clinic operates under a Board of Directors with a statutory auditor. A certified tax accountant and a licensed attorney serve as standing directors, providing a governance structure that integrates clinical, operational, financial, and legal oversight.
Cellforce One follows the principle that regenerative-medicine consultation should be documented, explained, and reviewed through physician judgment rather than presented as a uniform package.
Peer-reviewed research may help explain immune surveillance, inflammation, and tissue-repair mechanisms. Public-facing explanations remain research background and do not replace individual diagnosis, specialist care, or physician judgment.
MRI, bloodwork, inflammation markers, and prior medical records are used to organize the current condition. Follow-up data may be reviewed by physicians when it is clinically useful.
Enquiries, appointments, and medical visa consultations for international visitors are all welcome. Strictly by appointment, with full confidentiality.